OncLive |
Latest Data Further Support Ibrutinib’s Efficacy in CLL
OncLive Combining ibrutinib with the chemoimmunotherapy regimen of bendamustine (Treanda) plus rituximab (Rituxan) demonstrated a high level of activity and was tolerable for patients with relapsed or refractory CLL.1 Presenting the final results of the 30 … Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell MalignanciesMarketWatch |
Low Cost Insulin at 19 GHs Soon – The New Indian Express
The New Indian Express |
Low Cost Insulin at 19 GHs Soon
The New Indian Express “The subsidised rates will be for those who have undergone transplant surgery in a private hospital but cannot afford to buy these medicine,” another official said. Officials added that both insulin and drugs would be purchased wholesale by the Tamil … |
Proof of Heaven? The Science Behind Near-Death Experiences – Fora.tv (blog)
Fora.tv (blog) |
Proof of Heaven? The Science Behind Near-Death Experiences
Fora.tv (blog) Neurosurgeon Eben Alexander suffered a meningitis-induced coma in 2008, and after 7 days of brain death was revived, convinced he’d seen from worm’s eye to wormhole. In Proof of Heaven, he argues that materialism and brain-worship are the real “fairy … |
Kelly Thomas Trial update: Doctor testifies Thomas was in 'critical' condition … – 89.3 KPCC
89.3 KPCC |
Kelly Thomas Trial update: Doctor testifies Thomas was in ‘critical’ condition …
89.3 KPCC Rackauckas asked Lekawa what caused Thomas’ death. Lekawa: “His heart stopped in the field and a lack of oxygen to the brain caused irreversible brain injury and brain death.” On further questioning from Rackauckas, Lekawa connected actions during the … |
Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in … – 4-traders (press release)
|
Celgene Corporation : Studies Evaluating REVLIMID® (Lenalidomide) in …
4-traders (press release) In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an … |
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASH – MarketWatch
Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASHMarketWatchIn the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction i…
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH – Business Wire (press release)
|
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Business Wire (press release) In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an … |
Charlottetown man makes 100th blood donation – The Guardian Charlottetown
The Guardian CharlottetownCharlottetown man makes 100th blood donationThe Guardian CharlottetownBrandon Wu, a phlebotomist with the Canadian Blood services in Charlottetown prepares Paul Trewin for his blood donation Monday night. Trewin, who lives in …
Positive Data on Infinity Pharma Candidate – Zacks.com
|
Positive Data on Infinity Pharma Candidate
Zacks.com The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY)/(BIIB – Analyst Report) Rituxan (rituximab) and chemotherapy and who have … Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin …Business Wire (press release) Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B …MarketWatch |
Anakinra showed benefits in diastolic heart failure – Family Practice News Digital Network
|
Anakinra showed benefits in diastolic heart failure
Family Practice News Digital Network DALLAS – Interleukin-1 blockade resulted in significantly improved exercise capacity and a corresponding reduction in systemic inflammation in patients with heart failure with preserved ejection fraction in the small, pilot D-HART study. “These results … |